Web2 mei 2016 · MYK-461, is an orally administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM. Three Phase 1 clinical trials have been initiated to assess MYK-461’s... Web28 jun. 2024 · The PIONEER-HCM (A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction) trial was a phase II, non-randomized, open-label study of mavacamten in 21 symptomatic patients (NYHA Class II-III) with oHCM in which mavacamten was …
In vitro and in vivo pharmacokinetic characterization of …
Web2 apr. 2024 · 而在16年就有研究表明，MYK-461（即mavacamten）能够改善猫HOCM的左室流出道梗阻；20年11月又有报道使用MYK-581（mavacamten的替代品）治疗猫HOCM不仅能减轻过度收缩和 流出道梗阻，而且改善了心室充盈和减轻舒张末期压力。. 综合以上研究，我认为mavacamten或者其代替品 ... Web14 dec. 2016 · MYK-461 is a recently-described, mechanistically novel small molecule that acts at the sarcomere to specifically inhibit contractility that has been proposed as a … clerk of court chowan county nc
MyoKardia Receives Orphan Drug Designation for MYK-461 for …
Web31 dec. 2014 · The purpose of this study is to establish initial safety, tolerability, pharmacokinetics and pharmacodynamics of MYK-461 in human subjects. This is a … WebMYK-461 is a myosin inhibitor that selectively decreases the ATPase activity of cardiac myosin heavy chain, thus it is potentially for the treatment of hypertrophic … Web5 okt. 2024 · Mavacamten (MYK-461) is an oral, allosteric modulator of cardiac myosin being developed initially for symptomatic, obstructive hypertrophic cardiomyopathy (HCM). BMS said it planned to submit an... clerk of court civil records